MEDIPHARM LABS CORP (LABS.CA) Stock Fundamental Analysis

TSX:LABS • CA58504D1006

0.07 CAD
+0.01 (+7.69%)
Last: Feb 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, LABS scores 2 out of 10 in our fundamental rating. LABS was compared to 33 industry peers in the Pharmaceuticals industry. The financial health of LABS is average, but there are quite some concerns on its profitability. While showing a medium growth rate, LABS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • LABS had negative earnings in the past year.
  • In the past year LABS has reported a negative cash flow from operations.
  • LABS had negative earnings in each of the past 5 years.
  • LABS had a negative operating cash flow in each of the past 5 years.
LABS.CA Yearly Net Income VS EBIT VS OCF VS FCFLABS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -17.22%, LABS is not doing good in the industry: 60.61% of the companies in the same industry are doing better.
  • The Return On Equity of LABS (-21.20%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -17.22%
ROE -21.2%
ROIC N/A
ROA(3y)-28.72%
ROA(5y)-40.33%
ROE(3y)-34.34%
ROE(5y)-50.73%
ROIC(3y)N/A
ROIC(5y)N/A
LABS.CA Yearly ROA, ROE, ROICLABS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • Looking at the Gross Margin, with a value of 25.87%, LABS is doing worse than 66.67% of the companies in the same industry.
  • In the last couple of years the Gross Margin of LABS has declined.
  • The Profit Margin and Operating Margin are not available for LABS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 25.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-3.36%
LABS.CA Yearly Profit, Operating, Gross MarginsLABS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • LABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for LABS has been increased compared to 1 year ago.
  • LABS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for LABS has been reduced compared to a year ago.
LABS.CA Yearly Shares OutstandingLABS.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
LABS.CA Yearly Total Debt VS Total AssetsLABS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -2.10, we must say that LABS is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -2.10, LABS is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.01 indicates that LABS is not too dependend on debt financing.
  • With an excellent Debt to Equity ratio value of 0.01, LABS belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -2.1
ROIC/WACCN/A
WACC9.06%
LABS.CA Yearly LT Debt VS Equity VS FCFLABS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • LABS has a Current Ratio of 3.20. This indicates that LABS is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 3.20, LABS belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
  • LABS has a Quick Ratio of 2.27. This indicates that LABS is financially healthy and has no problem in meeting its short term obligations.
  • LABS has a better Quick ratio (2.27) than 84.85% of its industry peers.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 2.27
LABS.CA Yearly Current Assets VS Current LiabilitesLABS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 22.50% over the past year.
  • The Revenue has grown by 18.06% in the past year. This is quite good.
  • LABS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.15% yearly.
EPS 1Y (TTM)22.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)18.06%
Revenue growth 3Y24.58%
Revenue growth 5Y-20.15%
Sales Q2Q%24.7%

3.2 Future

  • The Earnings Per Share is expected to grow by 36.84% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, LABS will show a quite strong growth in Revenue. The Revenue will grow by 14.57% on average per year.
EPS Next Y54.1%
EPS Next 2Y36.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.37%
Revenue Next 2Y14.57%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LABS.CA Yearly Revenue VS EstimatesLABS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
LABS.CA Yearly EPS VS EstimatesLABS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.1 -0.2 -0.3

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LABS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LABS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LABS.CA Price Earnings VS Forward Price EarningsLABS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LABS.CA Per share dataLABS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04 0.06 0.08 0.1

4.3 Compensation for Growth

  • LABS's earnings are expected to grow with 36.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.84%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for LABS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDIPHARM LABS CORP

TSX:LABS (2/13/2026, 7:00:00 PM)

0.07

+0.01 (+7.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-30
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.36%
Ins Owner ChangeN/A
Market Cap29.74M
Revenue(TTM)46.10M
Net Income(TTM)-8.03M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-308.5%
Min EPS beat(2)-390.2%
Max EPS beat(2)-226.8%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)6.69%
Min Revenue beat(2)1.03%
Max Revenue beat(2)12.35%
Revenue beat(4)4
Avg Revenue beat(4)5.55%
Min Revenue beat(4)0.49%
Max Revenue beat(4)12.35%
Revenue beat(8)6
Avg Revenue beat(8)0.54%
Revenue beat(12)6
Avg Revenue beat(12)-4.9%
Revenue beat(16)7
Avg Revenue beat(16)-3.8%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-20%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.65
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.11
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.22%
ROE -21.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 25.87%
FCFM N/A
ROA(3y)-28.72%
ROA(5y)-40.33%
ROE(3y)-34.34%
ROE(5y)-50.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-3.36%
F-Score5
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.89%
Cap/Sales 0.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.2
Quick Ratio 2.27
Altman-Z -2.1
F-Score5
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)18.2%
Cap/Depr(5y)27.57%
Cap/Sales(3y)1.89%
Cap/Sales(5y)6.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y54.1%
EPS Next 2Y36.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)18.06%
Revenue growth 3Y24.58%
Revenue growth 5Y-20.15%
Sales Q2Q%24.7%
Revenue Next Year13.37%
Revenue Next 2Y14.57%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year84.07%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.89%
OCF growth 3YN/A
OCF growth 5YN/A

MEDIPHARM LABS CORP / LABS.CA FAQ

What is the ChartMill fundamental rating of MEDIPHARM LABS CORP (LABS.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LABS.CA.


What is the valuation status for LABS stock?

ChartMill assigns a valuation rating of 1 / 10 to MEDIPHARM LABS CORP (LABS.CA). This can be considered as Overvalued.


How profitable is MEDIPHARM LABS CORP (LABS.CA) stock?

MEDIPHARM LABS CORP (LABS.CA) has a profitability rating of 0 / 10.